Delayed gadoxetate MRI improves liver tumor delineation during MR-guided adaptive SBRT

Gadoxetate-enhanced MRI at 20–30 minutes improved liver tumor visibility and increased interobserver contour agreement from Dice 0.84 to 0.92.

KEY POINTS

  • This retrospective study from City of Hope evaluated gadoxetate disodium (Eovist) during 0.35-T MR-guided adaptive stereotactic body radiotherapy for primary and secondary liver tumors. The cohort included 23 patients with 37 treated liver lesions between December 2023 and November 2024, receiving a median 50 Gy in three to five fractions. Four experienced radiation oncologists independently assessed 159 TRUFI MRI acquisitions obtained before contrast, at 1–15 minutes, and at 20–30 minutes after injection.
  • Delayed post-contrast imaging significantly improved tumor visualization and confidence in target delineation. Mean visibility scores increased from 3.25 before contrast to 3.73 at 1–15 minutes and 4.45 at 20–30 minutes on a five-point scale. Similarly, confidence in tumor-border delineation increased from 3.06 to 3.58 and 4.38, respectively, with late imaging significantly outperforming both earlier acquisitions (p<0.001).
  • The benefit was not uniform across all liver lesions. Contrast was judged helpful in 54.1% of tumors and not helpful in 27.0%, while 18.9% lacked complete imaging at all three time windows. The authors identified better differentiation of tumor from normal liver during the delayed hepatobiliary phase, supporting selective use of contrast when lesions are difficult to identify on standard low-field TRUFI imaging.
  • Quantitative analysis in six selected patients showed improved interobserver contour agreement. Across four physicians and 24 contour comparisons, median Dice similarity increased from 0.84 without contrast to 0.92 with delayed contrast (p<0.001). The estimated volume of potentially missed tumor, defined relative to the post-contrast reference contours, decreased from 3.68 to 0.68 cm³ (p<0.001). However, Hausdorff distance and excess healthy-liver contour volume did not significantly improve across the complete six-patient sample.
  • The largest improvements occurred when contrast meaningfully increased tumor conspicuity. In the three patients benefiting most from gadoxetate, Dice similarity increased from 0.75 to 0.92 (p=0.005), while HD90 decreased from 4.18 to 2.00 mm and HD95 from 4.99 to 2.24 mm. The estimated untreated tumor volume decreased from 1.72 to 0.62 cm³. In the three patients without substantial visibility improvement, most geometric endpoints showed no significant change.
  • Gadoxetate administration was well tolerated in the evaluated clinical cohort. All 23 patients received contrast during their three- to five-fraction SBRT courses, with no reported grade ≥2 adverse reactions attributable to contrast. However, delayed imaging requires additional time during an already resource-intensive MR-guided adaptive workflow, potentially affecting patient throughput; the study did not provide a controlled comparison of total workflow duration with and without contrast.
  • Improved contour agreement should not be equated with validated target accuracy or improved tumor control. The quantitative analysis included only six deliberately selected patients, and the reference contour was derived from post-contrast physician delineations rather than independent pathological ground truth. No comparative target-dose accumulation, geographic-failure outcomes, local control, or long-term toxicity analysis was performed, and applicability to higher-field MR-Linac systems remains uncertain.

CLINICAL TAKEAWAY

Gadoxetate-enhanced MRI acquired approximately 20–30 minutes after injection may improve tumor conspicuity and reduce contouring uncertainty during low-field MR-guided liver SBRT, particularly for poorly visualized lesions. Selective contrast administration could improve target definition, but larger prospective studies are needed to determine its dosimetric and clinical value and to balance imaging benefits against treatment-workflow demands.

SOURCE

Practical Radiation Oncology

Browse more research Suggest a correction